Chandler Robinson - Jul 14, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Executive Officer, Director
Signature: /s/ Quan Vu, Attorney-in-fact
Stock symbol: MNPR
Transactions as of: Jul 14, 2025
Transactions value $: -$671,936
Form type: 4
Date filed: 7/16/2025, 09:02 PM
Previous filing: Jul 2, 2025
Next filing: Oct 2, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Robinson Chandler	Chief Executive Officer, Director	1000 SKOKIE BLVD SUITE 350, WILMETTE	/s/ Quan Vu, Attorney-in-fact	2025-07-16	0001727334

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Exercise of in-the-money or at-the-money derivative security	$84.00	+16.8K	+22.87%	$0.01	90.3K	Jul 14, 2025	Direct	F1
transaction	MNPR	Common Stock	Sale	-$672K	-16.8K	-18.61%	$40.00	73.5K	Jul 14, 2025	Direct	F2
holding	MNPR	Common Stock						822K	Jul 14, 2025	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNPR	Stock Options	Exercise of in-the-money or at-the-money derivative security	$0	-16.8K	-100%	$0.00	0	Jul 14, 2025	Common Stock	16.8K	$0.01	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction involved a cash exercise of stock options.
F2	The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3	As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 822,255 shares. Dr. Robinson disclaims beneficial ownership of the 822,255 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F4	Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Robinson on February 20, 2017, for his services as a director and officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.